目的 探討維肝福泰片聯(lián)合恩替卡韋分散片治療活動(dòng)性代償期乙型肝炎肝硬化的臨床療效。方法 選擇2015年1月-2016年7月成都市雙流區(qū)第一人民醫(yī)院收治的活動(dòng)性代償期乙型肝炎肝硬化患者122例作為研究對(duì)象，采用隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組各61例。對(duì)照組口服恩替卡韋分散片，1片/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服維肝福泰片，3片/次，3次/d。觀察兩組的臨床療效，比較兩組的乙型肝炎病毒的脫氧核糖核酸（HBV-DNA）水平、血清肝功能指標(biāo)、肝脾影像學(xué)指標(biāo)和肝纖維化指標(biāo)。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為72.1%、93.4%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組HBV-DNA水平顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組HBV-DNA水平明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療24、48周后，兩組血清中丙氨酸氨基轉(zhuǎn)移酶（ALT）、總膽紅素（TBIL）、天門冬氨酸氨基轉(zhuǎn)移酶（AST）水平均明顯降低，白蛋白（ALB）均明顯升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些肝功能指標(biāo)的同期改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療24、48周后，兩組門靜脈內(nèi)徑（Dpv）、脾厚度、脾靜脈內(nèi)徑（Dsv）均明顯降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些肝脾影像學(xué)指標(biāo)同期明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療24、48周后，兩組透明質(zhì)酸（HA）、Ⅲ型前膠原（PC-Ⅲ）、層粘蛋白（LN）、Ⅳ型膠原（Ⅳ-C）水平均明顯降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些肝纖維化指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 維肝福泰片聯(lián)合恩替卡韋分散片治療活動(dòng)性代償期乙型肝炎肝硬化具有較好的臨床療效，可有效抑制HBV的復(fù)制，改善肝功能和肝纖維化，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To study the clinical effects of Weigan Futai Tablets combined with Entecavir Dispersible Tablets in treatment of hepatitis B cirrhosis in active compensatory period. Methods Patients (122 cases) with hepatitis B cirrhosis in active compensatory period in the First People's Hospital of Shuangliu District from January 2015 to July 2016 were randomly divided into control and treatment groups, and each group had 61 cases. Patients in the control group were po administered with Entecavir Dispersible Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Weigan Futai Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 48 weeks. After treatment, the clinical efficacies were evaluated, and HBV-DNA levels, liver function indexes, liver and spleen imaging indexes, and liver fibrosis indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 72.1% and 93.4%, respectively, and there was difference between two groups (P < 0.05). After treatment, the HBV-DNA levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the HBV-DNA levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment for 24 and 48 weeks, the levels of ALT, TBIL, and AST in two groups were significantly decreased, but the levels of ALB in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the liver function indexes in the treatment group were significantly better than those in the control group at the same time, with significant difference between two groups (P < 0.05). After treatment for 24 and 48 weeks, Dpv, splenic thickness, and Dsv in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the liver and spleen imaging indexes in the treatment group were significantly lower than those in the control group at the same time, with significant difference between two groups (P < 0.05). After treatment for 24 and 48 weeks, the levels of HA, PC-Ⅲ, LN, and Ⅳ-C in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the liver fibrosis indexes in the treatment group were significantly lower than those in the control group at the same time, with significant difference between two groups (P < 0.05). Conclusion Weigan Futai Tablets combined with Entecavir Dispersible Tablets has clinical curative effect in treatment of hepatitis B cirrhosis in active compensatory period, can effectively inhibit HBV replication, improve liver function and liver fibrosis, which has a certain clinical application value.